The year 2020 has been both devastating and energizing for the global MD&D industry as a whole. The COVID-19 pandemic, whose impact first shut down and then curtailed routine medical, hospital and surgical care around the world, delayed normal market growth which, even now, is threatened by a possible second, mutation-induced pandemic. Hardest hit have been companies that serve surgical markets and those dominated by office- and clinic-based services, e.g., aesthetics, hearing, dental. On the other hand, developers of IVD tests that diagnose the SARS-CoV-2 virus and manufacturers of infection control disposables, critical care and respiratory products have seen their revenues skyrocket to the point that some have been unable to keep up with demand. The result has been a roller coaster but mostly disappointing year for the industry, although MD&D companies can take comfort in the knowledge that they have not faced these hardships by themselves and, as an industry, have actually responded to the pandemic with great competence, ingenuity and care for their employees, patients, clinicians and stockholders.
Earlier in the year, the publisher released reports providing insights into: 1) the anticipated impact of the COVID-19 pandemic on the global MD&D market by major technology; and 2) MD&D companies’ apparent exposure to the pandemic based on the composition of their product portfolios. The current report provides a wrap up of the year’s positives and negatives. It forecasts 2020 revenues for 50 of the largest MD&D companies by franchise as well as forecasts for nearly 100 technologies grouped into 23 segments for 2020 and 2021. The publisher did not venture beyond 2021 except to comment in the text on how far full recovery for a technology market might stretch into that year.
This new report quantifies the impact that COVID-19 has had on the global MD&D market and forecasts how the publisher expects the market to rebound, by segment and by competitor.
Earlier in the year, the publisher released reports providing insights into: 1) the anticipated impact of the COVID-19 pandemic on the global MD&D market by major technology; and 2) MD&D companies’ apparent exposure to the pandemic based on the composition of their product portfolios. The current report provides a wrap up of the year’s positives and negatives. It forecasts 2020 revenues for 50 of the largest MD&D companies by franchise as well as forecasts for nearly 100 technologies grouped into 23 segments for 2020 and 2021. The publisher did not venture beyond 2021 except to comment in the text on how far full recovery for a technology market might stretch into that year.
This new report quantifies the impact that COVID-19 has had on the global MD&D market and forecasts how the publisher expects the market to rebound, by segment and by competitor.
Table of Contents
EXECUTIVE SUMMARY
2.0 COVID-19 IMPACT ON MD&D MARKETS BY TECHNOLOGY
3.0 COVID-19 IMPACT ON GLOBAL MD&D COMPANIES
List of Exhibits
Companies Mentioned
- 3M
- Abbott Laboratories
- AbbVie/Allergan plc
- Alcon
- Align Technology
- Arthrex
- Asahi Kasei
- B. Braun Melsungen
- Baxter International
- Becton Dickinson
- bioMerieux
- Boston Scientific
- Canon Medical Systems
- Cardinal Health
- Coloplast
- ConvaTec
- Cooper Companies
- Danaher Corporation
- Demant
- Dentsply Sirona
- Edwards Lifesciences
- Elekta
- Envista
- Fresenius SE & Co. KGaA
- FujiFilm
- GE Healthcare
- Getinge
- Hillrom
- Hologic
- Intuitive Surgical
- Johnson & Johnson
- Medtronic
- Mölnlycke
- Nipro
- Olympus Corporation
- Philips Healthcare
- ResMed
- Roche Diagnostics
- Siemens Healthineers
- Smith & Nephew
- Sonova
- Steris
- Straumann
- Stryker
- Sysmex
- Teleflex
- Terumo
- Thermo Fisher Scientific
- Varian Medical Systems
- Zimmer-Biomet